What is Sjögren-Larsson Syndrome

TL;DR: Sjögren-Larsson syndrome is a rare, inherited neurocutaneous disorder characterized by the classic clinical triad of intellectual disability, spasticity, and ichthyosis (scaly skin). It is caused by a deficiency in the enzyme fatty aldehyde dehydrogenase (ALDH3A2), which leads to the accumulation of toxic fatty aldehydes in the body.

What are the primary symptoms of Sjögren-Larsson syndrome?

The clinical presentation of Sjögren-Larsson syndrome typically involves three core features. Ichthyosis, or dry, scaling skin, is often present at birth or develops within the first few months of life. As children grow, they develop spasticity—a form of muscle stiffness—that most severely affects the legs, often leading to a "scissor gait." Intellectual disability is also a hallmark of Sjögren-Larsson syndrome, ranging from mild to severe, and is frequently accompanied by delayed speech development.

What causes Sjögren-Larsson syndrome?

Sjögren-Larsson syndrome is an autosomal recessive genetic disorder. This means an individual must inherit two copies of a mutated ALDH3A2 gene—one from each parent—to manifest the disease. The mutation leads to a deficiency in the fatty aldehyde dehydrogenase enzyme, which is essential for breaking down certain fatty substances in the body. When this enzyme fails, these substances accumulate in the skin, brain, and retina, causing the characteristic damage seen in patients with Sjögren-Larsson syndrome.

How common is Sjögren-Larsson syndrome?

Sjögren-Larsson syndrome is extremely rare, with an estimated prevalence of less than 1 in 250,000 individuals worldwide. While the condition is found globally, a higher frequency has been documented in northern Sweden due to a founder effect. Because it is a genetic condition, it affects males and females in equal numbers. Currently, 14 people with Sjögren-Larsson syndrome have joined the DiseaseMaps community, providing a vital space for sharing experiences and support.

Key clinical features of Sjögren-Larsson syndrome

• Congenital Ichthyosis: Thick, dark, or scaly skin present from early infancy.


• Neurological impairment: Spastic diplegia or tetraplegia and intellectual disability.


• Ocular findings: Glistening white dots (macular crystalline dystrophy) in the retina, which can be identified by an ophthalmologist.


• Speech and Motor Delays: Significant challenges in achieving developmental milestones.

Next steps

• Consult a clinical geneticist for diagnostic confirmation via ALDH3A2 gene sequencing or enzyme activity testing.


• Coordinate care with a multidisciplinary team, including neurologists, dermatologists, and physical therapists.


• Connect with the 14 members of the DiseaseMaps community to share insights and coping strategies.


• Visit the NIH GARD website to stay updated on the latest research and clinical trial opportunities.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Sjögren-Larsson syndrome overview.


• Orphanet: Rare disease database entry for Sjögren-Larsson syndrome (ORPHA: 825).


• OMIM (Online Mendelian Inheritance in Man): Entry #270200 for Sjögren-Larsson syndrome.


• PubMed: Clinical literature regarding the metabolic pathways of ALDH3A2 deficiency.